Oral immunotherapy is safe, effective for peanut-allergic preschoolers, study suggests

August 10, 2016, NIH/National Institute of Allergy and Infectious Diseases

Nearly 80 percent of peanut-allergic preschool children successfully incorporated peanut-containing foods into their diets after receiving peanut oral immunotherapy (OIT), a clinical trial has found. Peanut OIT involves eating small, gradually increasing amounts of peanut protein daily. Low-dose and high-dose OIT were safe and equally effective at suppressing allergic immune responses to peanut, investigators found. The work was partly supported by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Center for Advancing Translational Sciences, both part of the National Institutes of Health.

Previous studies with older children showed that peanut OIT can offer some protection against potentially life-threatening anaphylaxis caused by peanut exposure. In this study, researchers led by Wesley Burks, M.D., of the University of North Carolina at Chapel Hill, assessed whether giving OIT to younger children whose duration of was short could alter the course of the allergy and allow safe introduction of peanut into the diet.

The study team enrolled 40 peanut-allergic children aged 9 to 36 months. They randomly assigned participants to either high-dose peanut OIT with a target daily dose of 3,000 milligrams or a low-dose regimen with a target dose of 300 milligrams. Nearly all participants experienced some side effects, such as abdominal pain, but these were generally mild, and required little or no treatment. After receiving OIT for 29 months on average, participants avoided peanut completely for four weeks before attempting to reintroduce it into their diets.

Almost 80 percent of participants successfully reintroduced peanut with no allergic response, with no significant differences between the low-dose and high-dose arms. Comparison of the OIT-treated children with a control group of 154 peanut-allergic children who had avoided peanut showed that OIT-treated children were 19 times more likely to successfully incorporate peanut into their diets. The investigators are continuing to monitor the OIT-treated participants to assess the long-term treatment outcomes.

Currently, the NIAID-supported Immune Tolerance Network is conducting a randomized trial called IMPACT to determine whether peanut OIT can lower the risk of allergic reactions, induce tolerance and change the immune responses of -allergic children aged 12 to 48 months.

Explore further: Anaphylaxis risk up for siblings of peanut allergic children

More information: clinicaltrials.gov/ct2/show/NCT00932828

Related Stories

Anaphylaxis risk up for siblings of peanut allergic children

June 14, 2016
(HealthDay)—The risk of anaphylaxis is increased upon peanut introduction in siblings of children with peanut allergy, according to a study published online June 13 in Allergy.

Study suggests potential to predict peanut allergy immunotherapy outcomes

January 25, 2016
Oral immunotherapy for peanut allergy induces early, distinct changes in immune T-cell populations that potentially may help researchers determine which people will respond well to the therapy and which immune mechanisms ...

Oral immunotherapy for children's peanut allergy moves a step closer

January 29, 2014
After 6 months of OIT, 84-91% of the children could safely tolerate daily ingestion of 800 mg of peanut protein (roughly the equivalent of five peanuts), at least 25 times as much peanut protein as they could before the therapy.

Video: Why are people allergic to peanuts?

March 22, 2016
For 1 to 2 percent of the global population, eating a peanut butter and jelly sandwich could be potentially fatal. What makes peanut allergies so lethal, and why is the number of peanut-allergy sufferers on the rise?

Peanut allergy prevention strategy is nutritionally safe, study shows

June 10, 2016
Introducing peanut-containing foods during infancy as a peanut allergy prevention strategy does not compromise the duration of breastfeeding or affect children's growth and nutritional intakes, new findings show. The work, ...

Protection against peanut allergy by early consumption persists after 1 year of avoidance

March 4, 2016
Peanut allergy prevention achieved from early peanut consumption in at-risk infants persists after a one-year period of avoiding peanut, a clinical trial has found. The LEAP-ON clinical trial (Persistence of Oral Tolerance ...

Recommended for you

Scientists shine new light on link between obesity and cancer

November 12, 2018
Scientists have made a major discovery that shines a new, explanatory light on the link between obesity and cancer. Their research confirms why the body's immune surveillance systems—led by cancer-fighting Natural Killer ...

Fecal transplant effective against immunotherapy-induced colitis

November 12, 2018
For the first time, transplanting gut bacteria from healthy donors was used to successfully treat patients suffering from severe colitis caused by treatment with immune checkpoint inhibitors (ICIs). The study from The University ...

Two-pronged device enables maverick immune cells to identify and kill cancers

November 12, 2018
Immune cells called Gamma Delta T cells can act independently to identify and kill cancer cells, defying the conventional view of the immune system, reveals new research from the Francis Crick Institute and King's College ...

Suicide handshakes kill precursor T cells that pose autoimmune dangers

November 12, 2018
Ball lands in cup; cup triggers spring; spring clamps lever onto ball and holds it tight. That's a rough description of newly discovered cellular mechanisms that eliminate T cells that may cause autoimmune disorders.

Exosomes 'swarm' to protect against bacteria inhaled through the nose

November 12, 2018
Bacteria are present in just about every breath of air we take in. How the airway protects itself from infection from these bacteria has largely remained a mystery—until now. When bacteria are inhaled, exosomes, or tiny ...

Researchers find new pathway to regulate immune response, control diseases

November 9, 2018
Researchers at The University of Texas at Arlington have found a potential new pathway to regulate immune response and potentially control inflammatory diseases of the central nervous system such as meningitis and sepsis.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.